1. Home
  2. RILY vs CABA Comparison

RILY vs CABA Comparison

Compare RILY & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RILY
  • CABA
  • Stock Information
  • Founded
  • RILY 1973
  • CABA 2017
  • Country
  • RILY United States
  • CABA United States
  • Employees
  • RILY N/A
  • CABA N/A
  • Industry
  • RILY Investment Managers
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RILY Finance
  • CABA Health Care
  • Exchange
  • RILY Nasdaq
  • CABA Nasdaq
  • Market Cap
  • RILY 142.1M
  • CABA 118.8M
  • IPO Year
  • RILY 2007
  • CABA 2019
  • Fundamental
  • Price
  • RILY $3.16
  • CABA $1.10
  • Analyst Decision
  • RILY
  • CABA Strong Buy
  • Analyst Count
  • RILY 0
  • CABA 8
  • Target Price
  • RILY N/A
  • CABA $21.00
  • AVG Volume (30 Days)
  • RILY 858.4K
  • CABA 1.0M
  • Earning Date
  • RILY 04-29-2025
  • CABA 05-14-2025
  • Dividend Yield
  • RILY 17.86%
  • CABA N/A
  • EPS Growth
  • RILY N/A
  • CABA N/A
  • EPS
  • RILY N/A
  • CABA N/A
  • Revenue
  • RILY $854,383,000.00
  • CABA N/A
  • Revenue This Year
  • RILY N/A
  • CABA N/A
  • Revenue Next Year
  • RILY N/A
  • CABA N/A
  • P/E Ratio
  • RILY N/A
  • CABA N/A
  • Revenue Growth
  • RILY N/A
  • CABA N/A
  • 52 Week Low
  • RILY $2.67
  • CABA $0.99
  • 52 Week High
  • RILY $40.09
  • CABA $16.36
  • Technical
  • Relative Strength Index (RSI)
  • RILY 39.62
  • CABA 34.66
  • Support Level
  • RILY $2.74
  • CABA $1.01
  • Resistance Level
  • RILY $3.44
  • CABA $1.29
  • Average True Range (ATR)
  • RILY 0.34
  • CABA 0.14
  • MACD
  • RILY -0.02
  • CABA 0.01
  • Stochastic Oscillator
  • RILY 37.69
  • CABA 21.76

About RILY B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: